54.33 0.00 (0.00%)
After hours: 4:13PM EDT
|Bid||54.31 x 800|
|Ask||54.36 x 1100|
|Day's Range||53.26 - 54.48|
|52 Week Range||39.01 - 67.79|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.56|
SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Shares of MyoKardia, Inc. rose 6% on Monday morning after the company announced its treatment for obstructive hypertrophic cardiomyopathy (HCM) reduced symptoms in patients and was well-tolerated in a safety-and-efficacy trial. Obstructive HCM is a genetic heart disease in which the walls of the heart thicken and prevent the left ventricle from expanding properly, leading to reduced pumping capacity. In some patients, the pathway the blood takes to leave the heart - called the left ventricular outflow tract (LVOT) - gets blocked by the thickened muscle, restricting blood flow from the heart to the rest of the body. This causes patients to tire easily, even with only mild exertion. MyoKardia's safety-and-efficacy study, which is an extension of one of the company's Phase 2 trials of the drug, had 13 patients. After 24 weeks on mavacamten, the patients' LVOT obstructions were reduced to levels below the diagnosis threshold. Eight of the 10 patients saw significant improvements in their symptoms, with 7 getting to a point where they were considered to be asymptomatic. Mavacameten had little impact on left ventricular ejection fraction (a measure of the percentage of blood that leaves the heart each time it contracts), which remained normal. After 12 and 24 weeks, patients on mavacamten also showed statistically-significant improvements in certain biomarkers. NT-proBNP, a blood marker of cardiac wall stress, decreased about 10-fold. Left atrial volume index, a measure of pressure in the left ventricle, decreased, and a marker for left ventricular filling pressure also fell. There were no cardiac-related adverse events, and any adverse events reported were mostly mild and transient in nature, the company said. Shares of MyoKardia have fallen 18% in the year to date, while the S&P 500 has gained 4.6%.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker data for its investigational drug, mavacamten, from the company’s PIONEER open-label extension (OLE) study. The PIONEER-OLE study enrolled a total of thirteen patients who previously completed the Phase 2 PIONEER-HCM trial. These data reflect the longest duration of mavacamten treatment reported to date. Mavacamten is being developed for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (oHCM), in an ongoing Phase 3 pivotal trial, known as EXPLORER-HCM. Patients with oHCM are at an increased risk of heart failure, atrial fibrillation, stroke and death, including sudden cardiac death. There are an estimated 410,000 people with oHCM in the United States, with approximately 65,000 currently diagnosed and seeking medical attention. The EXPLORER-HCM trial is enrolling 220 patients with oHCM. Patients will be randomized 1:1 to receive mavacamten or placebo for 30 weeks with a primary endpoint of clinical response. EXPLORER-HCM topline data is expected in the second half of 2020, with the completion of enrollment expected in the second half of this year.
The startup is tapping a wealth of genetic information in databases and a new wave of technology in its quest to figure out why some people with a genetic mutation can have a more-severe form of a disease than others with the same mutation.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the.
When Big Pharma sneezes, small biotechs can catch a cold that can shed millions of dollars in potential "bio bucks."
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times Read More...
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President. Mr. Fairey will have global responsibility for oversight of all aspects of commercial operations and serve as a key member of MyoKardia’s executive leadership team. “Bill is a leader with a strong and relevant track record in building mission-driven, high-performing teams that have brought important therapies to patients with few if any options,” said Tassos Gianakakos, Chief Executive Officer of MyoKardia.
just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.
Is MyoKardia, Inc. (NASDAQ:MYOK) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as MyoKardia Inc (NASDAQ:MYOK), with a market capitalization of US$2.5b, rarely draw their attention from the investing community. Read More...
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MyoKardia is developing mavacamten for the chronic treatment of hypertrophic cardiomyopathy (HCM), a heritable disease caused by the presence of too many cross-bridges formed between the heart muscle proteins myosin and actin. Mavacamten is intended to normalize this excess cross-bridge formation, which underlies the hypercontractility, or elevated force of contraction, and the reduced compliance, or ability of the left ventricle to relax and fill with oxygenated blood, that are both characteristic of HCM.